Preparation and in vitro antitumor effects of&amp;nbsp;cytosine arabinoside-loaded genipin-poly-L-glutamic acid-modified bacterial magnetosomes

Liu, Yuangang; Dai, Qinglei; Wang, Shibin; Deng, Qiongjia; Wu, Wenguo; Chen, Ai-Zheng

doi:10.2147/ijn.s76123

Cited by 28 publications

(32 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the drug loading of ABMs-GP and ABMs-G by covalent cross-linking is lower than that of ABMs; it may be because the reaction process is affected by various other factors such as pH, temperature, and concentration. In this paper, we selected the optimum condition of our previous study [20]. The other factor is the steric effect of intermolecular reaction, which inhibits the experiment process.…”

Section: Evaluation Of the Amount Of Ara-c Immobilized To Bmsmentioning

confidence: 99%

“…These are composed of iron oxide or iron sulfide minerals enveloped by lipid membrane rich in amino groups [18,19]. In addition, previous literatures have evidenced that BMs are used to deliver various therapeutic agents such as drugs [20,21], enzyme [22], and DNA [23]. In a case, the activity of glucose oxidase immobilized BMs is 40 times effective than those immobilized on artificial magnetite particles [24].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Investigation of Various Cross-Linking Methods for the Immobilization of Cytosine Arabinoside on Bacterial Magnetosomes

Dai

Wang

et al. 2017

Journal of Nanomaterials

Self Cite

View full text Add to dashboard Cite

Bacterial magnetosomes (BMs) have emerged as potential drug delivery vehicles, possessing an iron oxide or iron sulfide core surrounded by a natural lipid membrane shell. In this study, we immobilized cytosine arabinoside (Ara-C) effectively on BMs by using various methods such as direct absorption (ABMs), and others include different cross-linkers such as genipin (GP) and glutaraldehyde (G). A well-dispersed Ara-C coupled bacterial magnetosomes resulted in significantly higher negative charge than that of naked BMs (−11.5±0.3 mV) confirming the drug loading. Out of all methods, direct absorption process led to the highest encapsulation efficiency and drug loading of88.2±4.3% and46.9±1.2%, respectively. These designs have shown the long-term drug release behavior without an initial burst release. Our results indicate that BMs-based nanoconjugates will potentially find widespread applications in pharmaceutical field.

show abstract

Section: Evaluation Of the Amount Of Ara-c Immobilized To Bmsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Investigation of Various Cross-Linking Methods for the Immobilization of Cytosine Arabinoside on Bacterial Magnetosomes

Dai

Wang

et al. 2017

Journal of Nanomaterials

Self Cite

View full text Add to dashboard Cite

show abstract

“…Bacterial magnetosomes (BMs) have emerged as a novel and efficient material due to their advantages of excellent biocompatibility and abundant bioactive sites in the membrane. 19,20 BMs are membrane-covered nanocrystals of magnetic iron oxide or iron sulfide synthesized by magnetotactic bacteria. 21 The advantageous properties of them make BMs a prior candidate for the delivery of proteins, chemotherapeutic drugs, and genes, among others.…”

Section: Introductionmentioning

confidence: 99%

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro

Long¹,

Dai²,

Zhou³

et al. 2018

IJN

Self Cite

View full text Add to dashboard Cite

In recent times, co-delivery of therapeutics has emerged as a promising strategy for treating dreadful diseases such as cancer.Materials and methodsIn this study, we developed a novel nanocarrier based on bacterial magnetosomes (BMs) that co-loaded with siRNA and doxorubicin (DOX) using polyethyleneimine (PEI) as a cross-linker (BMs/DP/siRNA). The delivery efficiency of siRNA as well as the pH-responsive release of DOX, and synergistic efficacy of these therapeutics in vitro were systematically investigated.ResultsThe structure of DOX–PEI (DP) conjugates that synthesized via hydrazone bond formation was confirmed by 1H nuclear magnetic resonance (NMR). The in vitro release experiments showed that the DP conjugate (DOX-loading efficiency – 5.77%±0.08%) exhibited the long-term release behavior. Furthermore, the optimal BMs/DP/siRNA particle size of 107.2 nm and the zeta potential value of 31.1±1.0 mV facilitated enhanced cellular internalization efficiency. Moreover, the agarose gel electrophoresis showed that the co-delivery system could protect siRNA from degradation in serum and RNase A. In addition, the cytotoxicity assay showed that BMs/DP/siRNA could achieve an excellent synergistic effect compared to that of siRNA delivery alone. The acridine orange (AO)/ethidium bromide (EB) double staining assay also showed that BMs/DP/siRNA complex could induce cells in a stage of late apoptosis and nanocomplex located in the proximity of the nucleus.ConclusionThe combination of gene and chemotherapeutic drug using BMs is highly efficient, and the BMs/DP/siRNA would be a promising therapeutic strategy for the future therapeutics.

show abstract

“…We have reported that BMs can be successfully coupled to cytosine arabinoside (Ara-C) through the surface modification of BMs by poly- l -glutamic acid (PLGA) [17]. We hypothesized that this new system could be used to enhance the antitumor efficacy of drug combination therapy.…”

Section: Introductionmentioning

confidence: 99%

A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy

et al. 2016

Self Cite

View full text Add to dashboard Cite

To minimize the non-specific toxicity of drug combination during cancer therapy, we prepared a new system synthesized from bacteria to deliver the anticancer drugs cytosine arabinoside (Ara-C) and daunorubicin (DNR). In this study, we selected genipin (GP) and poly-l-glutamic acid (PLGA) as dual crosslinkers. Herewith, we demonstrated the preparation, characterization and in vitro antitumor effects of Ara-C and DNR loaded GP-PLGA-modified bacterial magnetosomes (BMs) (ADBMs-P). The results show that this new system is stable and exhibits optimal drug-loading properties. The average diameters of BMs and ADBMs-P were 42.0 ± 8.6 nm and 65.5 ± 8.9 nm, respectively, and the zeta potential of ADBMs-P (−42.0 ± 6.4 mV) was significantly less than that of BMs (−28.6 ± 7.6 mV). The optimal encapsulation efficiency and drug loading of Ara-C were 68.4% ± 9.4% and 32.4% ± 2.9%, respectively, and those of DNR were 36.1% ± 2.5% and 17.9% ± 1.6%. Interestingly, this system also exhibits long-term release behaviour sequentially, without an initial burst release. The Ara-C drug continued to release about 85% within 40 days, while DNR release lasted only for 13 days. Moreover, similar to free drugs, ADBMs-Ps are strongly cytotoxic to cancer cells in vitro (HL-60 cells), with the inhibition rate approximately 96%. This study reveals that this new system has a potential for drug delivery application in the future, especially for combination therapy.

show abstract

Preparation and in vitro antitumor effects of cytosine arabinoside-loaded genipin-poly-L-glutamic acid-modified bacterial magnetosomes

Cited by 28 publications

References 19 publications

Investigation of Various Cross-Linking Methods for the Immobilization of Cytosine Arabinoside on Bacterial Magnetosomes

Investigation of Various Cross-Linking Methods for the Immobilization of Cytosine Arabinoside on Bacterial Magnetosomes

Bacterial magnetosomes-based nanocarriers for co-delivery of cancer therapeutics in vitro

A Natural Bacterium-Produced Membrane-Bound Nanocarrier for Drug Combination Therapy

Contact Info

Product

Resources

About